BHC250509P9500
- 4.15
- 0.000.00%
Bausch Health Newsroom
A U.S.-U.K. Trade Deal May Not Offer Hope for Canada, Other Markets -- Market Talk
Bausch Health Companies Inc. (BHC): Among Billionaire John Paulson's Stocks With Huge Upside Potential
Bausch + Lomb Brief: Says Received European CE Mark Approval for Preloaded LuxLife Full Range of Vision Intraocular Lens
Canadian American Business Council CEO Says She Was 'Heartened' by Comments From Trump-Carney Meeting
Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Maintains Target Price $8
Canadian Export Growth to Countries Beyond U.S. Unlikely to Last -- Market Talk
Bausch Health, Salix Announce Data on Xifaxan After OHE Hospitalization
Bausch Health Up 3.5% In US Premarket As Says New Analysis Suggests Efficacy of Xifaxan
Xifaxan(R) (Rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated With Reduced Risk of 30-Day OHE Rehospitalization
Canada's Carney Seeks New Deals From Talks With Trump -- WSJ
Raymond James Maintains Bausch Health(BHC.US) With Hold Rating, Cuts Target Price to $8
Xifaxan (Rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated With Reduced Risk of 30-Day OHE Rehospitalization
Canadian Stock Movers for Monday | Parkland Corp Was the Top Gainer; Materials Led Gains
TD Cowen Maintains Bausch Health(BHC.US) With Hold Rating, Cuts Target Price to $7
Bausch Health Companies: Hold Rating Amid Lowered Earnings and Profitability Concerns
Bausch Health Is Maintained at Sector Perform by RBC Capital
Bausch Health Companies Analyst Ratings
RBC Capital Maintains Bausch Health(BHC.US) With Hold Rating, Raises Target Price to $10
Shareholders in Bausch Health Companies (NYSE:BHC) Have Lost 68%, as Stock Drops 3.3% This Past Week
Bausch Health | 10-Q: Q1 2025 Earnings Report